Add the specialty areas of your choice to tailor excemed.org to your professional interests.
Save & Create free account
No thanks, just apply selection
I already have an account. Login

User login

We offer our registered users tailored information, free online courses and exclusive content.

Can't find your password?
Reset it here.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Annual meeting in multiple sclerosis: MS: from disease management to patient management

Annual meeting in multiple sclerosis: MS: from disease management to patient management
  • Neurology
  • Multiple sclerosis
Symposium by Excemed
Friday, May 18 - Saturday, May 19 2012
Valencia, Spain

Accreditation

EACCME®

Event format

Course
Registration status
Closed

Overview

Research into the pathophysiology of multiple sclerosis (MS) and the mechanism of action of new drugs has, in recent years, produced a virtuous circle offering ever-new insights, enhancing our understanding of the disease and allowing optimization of treatment. The 2012 Serono Symposia International Foundation (SSIF) Annual Symposium will provide a review of these insights and offer the opportunity to discuss how to translate this increasing knowledge of management improvements for individual patients.

Learning objectives

By attending the conference, participants will:

  • be updated on MS pathophysiology and modes of action of individual drugs
  • discuss the use of standardized diagnostic criteria in daily practice
  • improve their skills in sharing information with patients to increase adherence
  • understand present and future biomarkers of response to treatment

Accreditation details

Serono Symposia International Foundation (www.seronosymposia.org) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The 2012 CME Neurology Annual meeting: “MS from disease management to patient management” to be held in Valencia, Spain on 18-19 May 2012 is designated for a maximum of nine hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA).  To convert EACCME credit to AMA PRA category 1 credit, please contact the AMA.

Scientific programme

Friday 18 May, 2012

 

Pharmacological targets and evolving pathophysiological concepts

 

Chairman: D.Bates (UK)

 

 

09.00 Improving understanding of mechanism of action of immunomodulatory drugs

B. Kieseier (Germany) | Video lecture

09.30 Neuroprotection and steps towards neuroregeneration: promising therapeutic targets

R. Gold (Germany)

10.00 Resetting the immune system: stem cell transplantation

A. Uccelli (Italy)

10.30 Efficacy profiles of MS drugs

G. Comi (Italy)

11.00 Monitoring drug safety in clinical practice
P. Vermersch (France)

 

Session II MS diagnosis and prognosis

 

Chairman: X. Montalban (Spain)

12.00 McDonald criteria 2010: making the diagnosis easier
A.J. Thompson (UK)

12.30 The diagnosis of MS before MS
M. Tintorè (Spain). This lecture was given by J. Sastre-Garriga

13.00 What can magnetic resonance imaging tell us about disease evolution in the individual patient?
D. Arnold (Canada)

14.30 Case study: Differential diagnosis - neuromyelitis optica vs MS
Presenter: P. Rieckmann (Germany)

Discussant: L. Moiola (Italy)

 

Session III Treatment monitoring

 

Chairman: G. Comi (Italy)

15.10 Biomarkers

G. Giovannoni (UK) View online video

15.40 MRI as a potential marker of treatment response in current clinical practice
A. Rovira (Spain)

16.10 Present and future roles of pharmacogenomics
J. Oksenberg (USA)

17.00 Assessment of treatment response
M.S. Freedman (Canada) Video Presentation

17.30 Case study: Treatment and treatment algorithms
Presenter: G. Comi (Italy)

Discussants: X. Montalban and O. Fernández (Spain)

 

 

 

Saturday 19 May, 2012

 

Session IV From disease management to patient management

 

Chairman: B. Casanova (Spain)                                                                                                                                               

 

09.00 The patient’s willingness to take risk

P. Rieckmann (Germany)

09.30 How to implement the patient–caregiver partnership in clinical practice
D. Langdon (UK)

10.00 Treatment adherence: how to measure it and how to improve it
J. Sastre-Garriga (Spain)

10.50 Case study: Treatment failure due to lack of adherence
Presenter: D. Langdon (UK)

Discussants: P. Rieckmann (Germany) and J. Sastre-Garriga (Spain)

11.30 Case study: Improved outcomes through tailored treatment
Presenter: D. Bates (UK)

Discussants: G. Giovannoni (UK) and P. Rieckmann (Germany)

 

Session IV From Disease management to patient management

 

Chairman: B. Casanova (Spain)

09.00 The patient’s willingness to take risk
P. Rieckmann (Germany)

09.30 How to implement the patient–caregiver partnership in clinical practice
D. Langdon (UK)

10.00 Treatment adherence: how to measure it and how to improve it
J. Sastre-Garriga (Spain)

10.50 Case study: Treatment failure  due to lack of adherence
Presenter: D. Langdon (UK)

Discussants: P. Rieckmann (Germany) and J. Sastre-Garriga (Spain)

11.30 Case study: Improved outcomes through tailored treatment
Presenter: D. Bates (UK)

Discussants: G. Giovannoni (UK) and P. Rieckmann (Germany)

Chair(s)

David Bates

Department of Neurology
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom

Xavier Montalban

Vall d’Hebron University Hospital
Neurology-Neuroimmunology Department
Multiple Sclerosis Centre of Catalonia (Cemcat)
Barcelona, Spain
St. Michael’s Hospital
Division of Neurology
University of Toronto
Toronto, Canada

Faculty

Disclosure of faculty relationships

 

Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of Serono Symposia International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non- EMEA/FDA-approved (off-label) uses of drugs:

Douglas Arnold He declared no potential conflict of interest. David Bates He declared receipt of grants, honoraria, consultation fees and contracts from Merck Serono, Bayer and Biogen.

Bonaventura Casanova He declared no potential conflict of interest.

Giancarlo Comi He declared receipt of honoraria or consultation fees from SSIF, Merck Serono, Novartis, Bayer Schering, Biogen, Sanofi, Teva, Actelion.

Oscar Fernández He declared no potential conflict of interest.

Mark S. Freedman He declared receipt of research or educational grants from Bayer Healthcare, Genzyme, EMD Canada. He also declared receipt of honoraria or consultation fees from Bayer Healthcare, Biogen Idec, EMD Canada, Novartis, Sanofi-Aventis, Teva, Canada Innovation. He is a member of the company advisory board or board of directors for Bayer Healthcare, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, Celgene.

Gavin Giovannoni He declared receipt of consulting fees from Bayer Schering Healthcare, Biogen Idec, Genzyme, GlaxoSmithKline, GW Pharma, Merck Serono, Novartis, Protein Discovery Laboratoires, Teva-Aventis, Vertex Pharmaceuticals, UCB Pharma, Pfizer.

Ralf Gold He declared receipt of grants and contracts from Biogen Idec, Teva, Merck Serono, Novartis. He also declared receipt of honoraria or consultation fees from Biogen Idec, Teva, Merck Serono, Novartis, CSL Behring, Baxter, Bayer. He is a member of the company advisory board orboard of directors for Biogen Idec, Teva, Novartis, Baxter.

Bernd C. Kieseier He declared receipt of honoraria and financial support for research from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, Talecris, Teva.

Dawn Langdon She declared receipt of grants, contracts, honoraria or consultation fees from Bayer Healthcare. She is a member of the company advisory board or board of directors for Bayer Healthcare. She declared participation in a company-sponsored speakers bureau for SSIF, Biogen Idec, Bayer Healthcare. She also declared benefits from a relationship with a commercial enterprise: Bayer Healthcare.

Lucia Moiola She declared no potential conflict of interest.

Xavier Montalban He declared receipt of honoraria or consultation fees: Bayer Schering, Biogen Idec, Merck-Serono, Novartis, Teva, Sanofi, Genzyme, Almirall.

Jorge Oksenberg He declared receipt of honoraria or consultation fees from Teva Pharmaceuticals.

Alex Rovira He declared receipt of honoraria or consultation fees from Bayer Schering Pharma, Merck Serono, Teva Pharmaceutical Industries Ltd and Biogen Idec. He is also a member of the company advisory board or board of directors for NeuroTEC, Bayer Schering Pharma and BTG International Ltd.

Jaume Sastre-Garriga He declared to be a member of the company advisory board or board of directors for Novartis. He also declared participation in company-sponsored speakers bureau for SSIF, Merck Serono, Novartis, Teva, Eisai.

Alan J. Thompson He declared receipt of honoraria or consultation fees from Biogen Idec, Eisai, Merck Serono, DIGNA Biotech, Novartis, SSIF, NIHR as a Senior Investigator. He is also a member of the company advisory board, or board of directors for MSIF International Medical and Scientific Board, NMSS Research Programs Advisory Committee. He declared benefit from a relationship with commercial enterprises: Sage Publications, Multiple Sclerosis Journal, Elsevier, Lancet.

Mar Tintorè She declared receipt of grants and contracts from Bayer Schering, Biogen Idec, Merck Serono, Teva, Sanofi-Aventis and Novartis. She also declared receipt of honoraria or consultation fees from Bayer Schering, Biogen Idec, Merck Serono, Teva, Sanofi-Aventis and Novartis. She is a member of the company advisory board or board of directors for Teva and Biogen Idec.

Antonio Uccelli He declared receipt of grants and contracts from Merck Serono, Sanofi-Aventis, Biogen Idec, Novartis. He declared receipt of honoraria or consultation fees from Genolech, Allergan, Biogen Idec, Biogen Dompè, CMSC, Merck Serono. He declared participation in company-sponsored speakers bureau for Merck Serono, Novartis, Sanofi-Aventis, Biogen Dompè.

Patrick Vermersch He declared receipt of grants and contracts from Biogen Idec, Merck Serono, Bayer and Sanofi. He declared receipt of honoraria or consultation fees from Biogen Idec, Almirall, Novartis, Bayer, Merck Serono, Teva, Sanofi.

The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA-approved (off-label) uses of drugs as of 8 May 2012.

Peter Rieckmann